Skip to main content
Premium Trial:

Request an Annual Quote

Bioinformatics Indian Biofx Vendor TCS Aims to Undercut Competition


Given the well-documented struggles (and occasional failures) of vendors hawking bioinformatics software, one might be forgiven for being skeptical about a company claiming to have the next big thing for the bioinformatics community.

But Tata Consultancy Services, a Hyderabad, India-based division of the massive Tata conglomerate, thinks there’s one aspect to its software that can’t be beat: price. TCS, with the help of the Indian government and academic collaborators, claims to have developed a suite of gene, protein, and small molecule analysis programs that not only surpasses current offerings on performance, but will also drastically undercut them at the checkout counter.

TCS is best known for providing software and IT consulting services to mainstream industries like financial services and telecommunications, but in recent years the company has also branched into the life sciences, offering software for applications such as managing clinical trials. In late 2001, Mathukumalli Vidyasagar, TCS’s executive vice president for advanced technology, began looking to get into bioinformatics. At the time, says Vidyasagar, TCS wanted to learn about the kinds of problems life sciences researchers were facing with the flood of data from genome sequencing projects. “We didn’t even know if there was a future for IT companies in bioinformatics,” he adds.

But then the Indian government stepped in. Given the high cost to Indian universities of purchasing licenses to comprehensive gene and protein analysis software such as Accelrys’ Discovery Studio, the government provided more than two dozen academic groups with funds to develop new bioinformatics algorithms in collaboration with Vidyasagar’s group at TCS. By this time, TCS had put together a group of 30 programmers and eight PhD scientists — five with expertise in life sciences — to assemble the technology produced by their academic partners into a commercializable suite of programs.

The result was the Tata Bio-Suite. The software package, currently undergoing beta testing by TCS’s academic and industry partners in India, contains eight modules: sequence analysis, genome analysis, comparative genomics, 3-D modeling for homology and threading applications, 3-D structure manipulations, protein structure analysis, thermodynamic and electrostatic simulations, and drug design. Bio-Suite, according to Vidyasagar, meets and in some cases exceeds the capabilities of currently available top-of-the-line software.

Yet the most attractive element to the software, adds Vidyasagar, is the price. Because of the relatively low cost of R&D in India, the Bio-Suite will be priced aggressively, he says, at about one fifth to one quarter the cost of comparable software programs. Cost savings of this magnitude will make the software affordable not only to Indian universities, but to small and mid-size biotechs across the globe as well, Vidyasagar adds.

And what makes him think TCS will succeed in a business sector littered with the rusting hulks of companies either sold or gone bankrupt? The companies that failed were unidimensional, he says, and were underfunded in light of the time required for the market to mature. “Furthermore, they didn’t control expenses at all. Software development and maintenance costs in India are very low.”

—John S. MacNeil


The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.